Open AccessPotent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against <i>FLT3</i>- mutant acute myeloid leukemia and <i>KMT2A</i>-rearranged acute lymphoblastic leukemia
Author(s) -
Lisa M Niswander,
Zachary Graff,
Christopher Chien,
John Chukinas,
Christina A. Meadows,
Lillie Leach,
Joseph P. Loftus,
M. Eric Kohler,
Sarah K. Tasian,
Terry J. Fry
Publication year - 2022
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2022.281456
Subject(s) - cancer research , chimeric antigen receptor , leukemia , myeloid leukemia , immunotherapy , antigen , myeloid , immunology , biology , medicine , immune system